Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.
about
Activation of rapid oestrogen signalling in aggressive human breast cancersCancer metastases: challenges and opportunitiesIntegrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screenGlobal phosphotyrosine proteomics identifies PKCδ as a marker of responsiveness to Src inhibition in colorectal cancerThe CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer.Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells.A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.Role of retinoic acid and platelet-derived growth factor receptor cross talk in the regulation of neonatal gonocyte and embryonal carcinoma cell differentiationExpression and function of MutT homolog 1 in distinct subtypes of breast cancer.Genetics of glioblastoma: a window into its imaging and histopathologic variability.Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers.Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells.PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid TumorsDrosophila Abelson kinase mediates cell invasion and proliferation through two distinct MAPK pathways.The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells.Src inhibitors in the treatment of metastatic bone disease: rationale and clinical dataMetastatic bone disease: role of transcription factors and future targets.The ETS family of oncogenic transcription factors in solid tumours.Progress towards the development of SH2 domain inhibitors.Targeted therapy in prostate cancer.Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity.Data-driven modeling of SRC control on the mitochondrial pathway of apoptosis: implication for anticancer therapy optimization.Breast cancer at bone metastatic sites: recent discoveries and treatment targets.A phase 2 trial of dasatinib in advanced melanoma.SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatmentImproved angiostatic activity of dasatinib by modulation with hydrophobic chainsCombination of dasatinib and curcumin eliminates chemo-resistant colon cancer cellsTherapeutic advances in women's cancersIdentification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors.Src inhibitors in suppression of papillary thyroid carcinoma growth.Role of estrogen receptor signaling in breast cancer metastasis.Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancerOrthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAFEffective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapyPhase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622Clinical nomogram to predict bone-only metastasis in patients with early breast carcinomaProteolysis of EphA2 Converts It from a Tumor Suppressor to an Oncoprotein
P2860
Q24300885-DD1B308A-1F5E-4310-9B0A-B6EA9B04DE53Q28088755-A8876B07-5753-45F7-A6A2-36CD03B46D4FQ28484181-4FC39DC1-920D-4E0B-A440-9D257D89A1EBQ28535249-E65F9B2E-CD87-4171-858B-FEC5B4319990Q30010104-5D9E136F-3F99-4FA0-BD0C-4FD477749781Q30416775-8DB0B792-1291-467A-A1D2-97E7041E4141Q30416923-B6FFF263-7FEA-4A9E-85A5-CE586BD74372Q30501331-2F6A2E18-22CE-48E1-84A6-141E9545FAA2Q33404541-B6F1FBD9-2217-4243-9D25-4B45899EE142Q33569641-9CD7AC0B-11E2-4924-8DC0-16D9E93C2BCAQ33598769-11A101D9-47B0-4925-943F-C4158A20555EQ33620506-A6379A02-CE54-4582-8505-9DE8EA24EF1CQ33641010-7B34D932-F819-49CF-9F40-B5BCD24BC662Q33778101-8662B21F-6980-4C8A-89F4-A7A22E592635Q33779210-13A91914-F843-4D29-9312-091336B7711BQ33882326-36F11853-1B10-4617-B34C-B0BA9C9294E5Q34056631-9566DBDA-7946-446B-BA5B-851BDBA71CFAQ34099289-2B01C182-A4DE-4042-B197-D30EC4C6A103Q34182834-30FA4C33-B7DC-4EB0-895F-4275795FFB03Q34217531-424BF751-8986-4E41-A6B1-5E28BC313A5FQ34555986-C1772D90-DB3E-4A7C-8EB1-052E7F3E7992Q34581878-FBBA6BEB-CE6D-46BF-AE33-0C2D05B66994Q34634763-11EFC69D-EED5-4B3E-9063-4275A2A744B4Q34670804-7572A523-7B8C-4B46-B60D-C3686E0C2293Q34671696-6A6864D0-7412-473D-9AF0-A01CACC18DF5Q34939979-0F48EEA4-A2B0-44D7-8CD9-69A300C31799Q35048145-C2846F8A-94C6-461B-B060-38F5F0CB0BD8Q35113027-77DEA8BF-A76A-4BAB-80B1-F525143E6A86Q35178869-9DB75D92-2EED-4E5E-86A6-7F2EFF11A716Q35184278-94490723-32FE-4FBC-9146-FA053A0587D3Q35418973-8206E478-CB06-4C32-8C58-9B34D4C9DE8BQ35456945-56B83BDE-B1E8-4A6F-97C4-656C0F76842CQ35457965-39245E88-247C-46F6-AF9C-8B7C53579465Q35684545-8B536821-B666-4333-9E0E-BE6ACFAB27A6Q35786826-8F992F04-F708-4761-B43D-FCCC99B4916AQ35914464-BC6E7630-037D-4AAF-9FD8-7F159F7E25D5Q35998388-257D8202-0C5B-4BF1-AA1C-9A043C2C957CQ36090747-ACE40086-8FC9-42A2-AD61-DEA3148FD919Q36295018-B2FAF96E-D9F3-4EA2-918F-EB7F20992F8AQ36380708-72662EAE-28E3-401D-9B67-17D19CD4BB3E
P2860
Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dasatinib: a potent SRC inhibi ...... the treatment of solid tumors.
@en
Dasatinib: a potent SRC inhibi ...... the treatment of solid tumors.
@nl
type
label
Dasatinib: a potent SRC inhibi ...... the treatment of solid tumors.
@en
Dasatinib: a potent SRC inhibi ...... the treatment of solid tumors.
@nl
prefLabel
Dasatinib: a potent SRC inhibi ...... the treatment of solid tumors.
@en
Dasatinib: a potent SRC inhibi ...... the treatment of solid tumors.
@nl
P2860
P1476
Dasatinib: a potent SRC inhibi ...... the treatment of solid tumors.
@en
P2093
Christopher Logothetis
John Araujo
P2860
P304
P356
10.1016/J.CTRV.2010.02.015
P577
2010-03-11T00:00:00Z